1999
DOI: 10.1038/70746
|View full text |Cite
|
Sign up to set email alerts
|

Semirational design of a potent, artificial agonist of fibroblast growth factor receptors

Abstract: Fibroblast growth factors (FGFs) are being investigated in human clinical trials as treatments for angina, claudication, and stroke. We designed a molecule structurally unrelated to all FGFs, which potently mimicked basic FGF activity, by combining domains that (1) bind FGF receptors (2) bind heparin, and (3) mediate dimerization. A 26-residue peptide identified by phage display specifically bound FGF receptor (FGFR) 1c extracellular domain but had no homology with FGFs. When fused with the c-jun leucine zippe… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
32
0

Year Published

2001
2001
2019
2019

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 61 publications
(35 citation statements)
references
References 36 publications
3
32
0
Order By: Relevance
“…In another case, a 19-residue peptide was selected for binding an FGFR. When the peptide was dimerized by fusion to the c-Jun leucine zipper, it activated the FGFR in presence of a synergistic binder, heparin, with a potency similar to that of FGF (64). Thus, small mimetics can be found for the cytokine receptors.…”
Section: Mechanisms Of Horizontal Signaling Complexesmentioning
confidence: 99%
“…In another case, a 19-residue peptide was selected for binding an FGFR. When the peptide was dimerized by fusion to the c-Jun leucine zipper, it activated the FGFR in presence of a synergistic binder, heparin, with a potency similar to that of FGF (64). Thus, small mimetics can be found for the cytokine receptors.…”
Section: Mechanisms Of Horizontal Signaling Complexesmentioning
confidence: 99%
“…A 26-residue peptide identified by phage display specifically bound FGF receptor (FGFR) 1c extracellular domain, but had no homology with FGFs. When fused with the c-jun leucine zipper domain, which binds heparin and forms homodimers, the polypeptide specifically reproduced the mitogenic and morphogenic activities of basic FGF with similar potency (EC50 = 240 pM) [38].…”
Section: Cytokine and Growth Factor Receptorsmentioning
confidence: 99%
“…In this study FGF2 was used as an example to help improve and characterise the coating platform but is unlikely to be effective for systemic applications in vivo as a whole growth factor molecule. To target these receptors more effectively, small fragments or peptides could be used [32]. Lower affinity peptides should have greater selectivity through the avidity effect of multiple peptides displayed on the surface of a vector.…”
Section: H Exposure To Cells With Transgene Expression Evaluated Aftementioning
confidence: 99%